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Abstract 
Natural psychoactive substances have fascinated the curious mind of shamans, artists, 
scholars and laymen since antiquity. During the twentieth century, the chemical com-
position of the most important psychoactive drugs, that is opium, cannabis, coca and 
“magic mushrooms”, has been fully elucidated. The mode of action of the principal in-
gredients has also been deciphered at the molecular level. In the past two decades, the 
use of herbal drugs, such as kava, kratom and Salvia divinorum, began to spread beyond 
their traditional geographical and cultural boundaries. The aim of the present paper is 
to briefly summarize recent findings on the psychopharmacology of the most prominent 
psychoactive natural products. Current knowledge on a few lesser-known drugs, includ-
ing bufotenine, glaucine, kava, betel, pituri, lettuce opium and kanna is also reviewed. In 
addition, selected cases of alleged natural (or semi-natural) products are also mentioned.
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INTRODUCTION
During the past 200 years, there has been major pro-
gress in our understanding of the composition and ef-
fects of many psychoactive natural products, particular-
ly those that have therapeutic uses. This article reviews 
the pharmacohistory, the chemistry, the mode of action, 
and, where pertinent, the toxicology of some globally 
emerging and some lesser-known psychoactive natural 
products with emphasis on recent findings. Some of 
these substances or potions have been known for dec-
ades but became popular on the recreational drug scene 
only recently; the prevalence and extent of their use, 
however, are not captured by regular epidemiological 
questionnairs. Others appear to have only marginal use, 
yet they provide an interesting insight into how new 
drugs emerge from obscurity. Some of the substances 
were detected for the first time in Europe and reported 
to the Early warning system (EWS) of the European 
Monitoring Centre for Drugs and Drug Addiction as a 
“new psychoactive substance”1 just recently. Regulatory 
aspects are only briefly mentioned since drug legislation 
varies from country to country and is currently undergo-
ing dynamic changes.
Historical background of psychoactive natural 
products research
The biochemical machinery of an organism generates 
many structurally related chemicals (Nature’s “combinato-
rial library”) of which some have physiological or ecological 
relevance, aiding survival of the producer in a hostile envi-
ronment. For mankind, natural2 products also represent an 
ancient and rich source of bioactive substances [1]. 
The unique psychoactivity of these drugs has fascinated 
shamans, artists, writers, scholars and laymen alike since 
antiquity. Through a lengthy, and sometimes dangerous, 
process of trial and error each culture discovered and de-
veloped a natural product-based tradition of “mind alter-
ing”. In modern societies, the most extensively produced 
and widely consumed psychoactive drugs, that is alcoholic 
beverages, caffeine-containing drinks and tobacco products 
are all of natural origin.
Psychoactive natural products display an astonishing 
structural diversity and may come from three sources: 
plants, microorganisms or animals. According to estimates, 
the number of plants with proven or reputed psychoactivity 
exceeds 300 [2]; a recent compendium by the European 
Food Safety Authority lists hundreds of addictive or psy-
O, mickle is the powerful grace that lies
In herbs, plants, stones, and their true qualities
William Shakespeare (Romeo and Juliet)
1. European Council Decision 2005/387/JHA stipulates a “new 
psychoactive substance” as a new narcotic or psychotropic drug, in pure 
form or in preparation, that is not controlled by the relevant 1961 or 
1971 United Nations Conventions. However, a new mode of use of a 
known “traditional” drug is often brought to the attention of the EWS 
of EMCDDA and relevant data are deposited in a new drugs database.
2. According to the Oxford Dictionary, the adjective “natural” refers 
to something that exists in or is derived from nature; not made or 
caused by humankind. The word “natural” is often, but erroneously, 
thought to be equivalent to “good” or “pure” as if many poisons, 
including nicotine, strychnine and botulinum toxin, were not 
products of nature.
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choactive botanical preparations [3]. The hallucinogenic 
properties of mushrooms have been known for millennia 
and over 200 fungal species that produce psychotropic sub-
stances have been described [4]. However, there are only 
sporadic reports on psychic effects elicited by deliberate or 
accidental ingestion of animals [5, 6] (for toads, see later).
The bioactive extracts obtained from an organism by self-
experiments or biochemical and receptor-based screening 
methods are typically suites of structurally related chemi-
cals interacting with a wide variety of biological targets. 
Furthermore, any single component of such a “chemical 
shotgun” may have more than one molecular target. In ad-
dition, one constituent may have high receptor affinity but 
low efficacy to elicit significant pharmacological response, 
while an other, sometimes minor, component may have low 
affinity but high efficacy thus the relevant pharmacological 
effect manifests only at a high dose (see, e.g., [7]). There-
fore, the overall psychosomatic response is complex and 
dose-dependent and this explains the versatility of many 
ethnobotanical preparations.
It has often been observed that the psychic and somatic 
effects of a natural preparation differ from those of the pure 
main ingredients indicating that minor constituents con-
tribute to or modulate the activity of the major component. 
Mixtures containing synergistically acting ingredients pose 
methodological difficulties: bioassays using purified sam-
ples might miss the activity observed for the crude extract.
The isolation of the alkaloid morphine from opium by 
Sertürner six generations ago (1805) laid the foundation of 
phytochemistry and modern pharmacy. Further research 
on opioids culminated on one hand in the chemical total 
synthesis of morphine in 1952 and, on the other, in the dis-
covery of endogenous opioid peptides and their receptors 
in the 1970s. Building on the results of these investigations, 
many (semi-)synthetic analgesics, cough suppressants, anti-
diarrheal agents as well as molecular probes for mode of ac-
tion studies have been developed [8]. Heroin, oxycodone, 
desomorphine, naloxone, pethidine, methadone, the fenta-
nils, dextromethorphan, loperamide, and ketazocine have 
become “household names” not only among specialists of 
medicine but also among those working in the broad field 
of addiction. Subsequently, the active principles of other 
natural psychoactive agents were also elucidated and, as 
shown in Table 1, the “Golden Area” of psychoactive natu-
ral products discovery appears to have lasted for almost two 
centuries.
A note of caution regarding olden literature: several 
chemicals have been isolated from exotic drugs. Yet, recent 
phytochemical re-analysis of many such plants detected 
these substances in trace amounts only (< 0.1%), a concen-
tration unlikely to elicit the reported effects of the prepara-
tion. In other instances, the activity of an isolated substance 
was not verified in bioassays. In these cases the genuine bio-
active component awaits identification. Publications solely 
relying on early literature thus must be assessed critically.
MAJOR EMERGING PSYCHOACTIVE 
NATURAL PRODUCTS
Khat
Khat refers to the evergreen shrub Catha edulis indig-
enous to East Africa. Khat also refers to the leaves and 
shoots of the plant chewed to provide mild stimulant ef-
fects. Khat has a variety of regional names such as mairungi 
(Uganda), miraa (Kenya), qat (Yemen), or tschat (Ethiopia 
and Somalia). The shrub is an intensively cultivated, high-
income cash crop in East Africa and the southwestern part 
of the Arabian Peninsula. In addition to supplying domestic 
markets, fresh khat bundles, each weighing 250-300 g, are 
nowadays shipped by airfreight into Europe, Australia and 
North America to ethnic groups immigrated from coun-
tries where khat-chewing is a tradition [9-13]. During the 
daily 3-6 hour-long afternoon chewing sessions, at least 
one bundle is consumed, mainly in social setting, to pro-
vide euphoric and stimulant affects. The number of regular, 
predominantly male, khat consumers is at least ten million 
although epidemiological data are lacking.
Several types of compounds have been isolated from 
khat, including amino acids, ascorbic acid, flavonoids, phe-
nylalkylamine alkaloids, sesquiterpene polyester alkaloids 
(cathedulins), steroids, tannins, and terpenoids. The main 
psychoactive constituent was identified in 1975 and named 
cathinone (Figure 1) [14]. The cathinone-content of the 
leaves typically ranges from 0.04 to 0.3 %. Biosynthetically 
related alkaloids also present in khat are cathine (i.e., norp-
seudoephedrine) (Figure 1), and norephedrine, though they 
are only slightly active. Data on the bioactivity of other khat 
constituents are scarce.
Cathinone is a chemically unstable aminoketone. In the 
leaves it undergoes enzymatic reduction into cathine (e.g., 
[15]), thus the harvested shoots lose psychoactivity within 
2-3 days explaining the chewers’ preference for fresh khat 
(see, e.g., [16]). Interestingly, the chemical synthesis of race-
mic “cathinone” by Schmidt in 1889 preceded by many dec-
ades the identification of the natural product; its tendency to 
undergo decomposition was also noted a century ago.
Khat and its main ingredients are amphetamine-like 
dopaminergic psychostimulants with peripheral sympa-
thomimetic effects [17, 18]. In the central nervous system, 
cathinone inhibits the reuptake of dopamine and norepi-
nephrine into presynaptic nerve terminals without affecting 
serotonin transport [19]. Several reports indicate that khat 
use may lead to dependence, induce psychoses and cause 
cardiovascular diseases [20-23], but robust information on 
the somatic and mental health problems associated with 
regular use is lacking. Due to intensive farming of the plant, 
pesticides may contaminate the bundles [24] although 
the health consequences of such contamination have not 
been investigated. The environmental, socio-economic and 
health problems associated with the production and use of 
khat have recently become a focus of scientific and political 
debates [25, 26]3. While cathinone and cathine are sched-
uled according to the UN Convention on Psychotropic 
Substances of 1971, khat leaves do not fall under any inter-
national regulatory system. Yet, Australia, several US states 
and European countries have recently introduced measures 
to control the trade of Catha edulis [9, 27].
It is interesting to follow the chronology of appearances 
of such aminoketone stimulants: first, in the late 1970s, the 
semi-synthetic methcathinone, i.e., the N-methyl deriva-
tive of cathinone (also called ephedrone indicating that it is 
made by oxidizing ephedrine) appeared on the drugs scene 
in the then-Soviet Union; a decade later, in 1989, meth-
cathinone was introduced into Michigan [28]; a decade lat-
3. See also presentations of a conference organized by the European 
Science Foundation in Linköping, 5-9 October, 2009. Available from: 
www.esf.org/serving-science/conferences/details/2009/confdetail274/
presentations.html. 
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er it reappeared in several countries. Around the same time, 
in 2003, synthetic cathinone containing capsules (“Hagi-
gat”) were beginning to be sold in kiosks in Israel [29]. In 
retrospect, these appearances seem to have been preludes 
to the subsequent alarming emergence of synthetic cathi-
nones (commonly referred to as “bath salts”). 
Salvia divinorum
The psychoactive mint Salvia divinorum, or the diviner’s 
sage, is indigenous to the highlands of the Oaxaca state 
in Mexico, where Mazatec shamans have been using it 
for medical purposes, in healing ceremonies and divina-
tory rituals. Traditionally, the fresh leaves are chewed or 
pressed to make a drink. Since the late 1990s, the “recrea-
tional” use of S. divinorum as an herbal hallucinogen has 
been spreading globally especially among young adults 
[30, 31]4. For this purpose, 0.25-0.75 grams of crushed 
dried leaves are smoked from a pipe or water bong to pro-
vide profound hallucinations and unique, “out-of-body” 
experiences that commence within a minute and last for 
15-20 minutes [32, 33].
The psychoactive principle of the leaves is salvinorin A 
(Figure 1). This non-nitrogenous, neoclerodane diterpene 
was isolated first by Ortega et al. in 1982. Independently, 
in 1984, the same compound was isolated and biologically 
characterized by Valdes et al., who called it “divinorin A”. 
Salvinorin A has not been detected in any other Salvia spe-
cies examined to date [34]. It is the most potent natural 
hallucinogen: inhalation of the vapors of doses equivalent 
to 200-500 microgram pure salvinorin A elicits strong hal-
lucinations with virtually no discernible somatic effects. 
This dose is comparable to the effective oral dose of the 
semi-synthetic LSD (lysergic acid diethylamide) (100 mi-
crogram) or the synthetic DOB (4-bromo-3,5-dimethoxy-
phenylisopropylamine) (1000 microgram), although the 
subjective effects are qualitatively different from those 
of any other known hallucinogens [32, 35-37]. The short 
duration of the effects is explained by the rapid, esterase-
catalyzed hydrolysis of the 2-O-acetate of salvinorin A to its 
inactive alcohol (salvinorin B) [38, 39].
Unlike classical hallucinogens that target serotonin (5-
HT) receptors, 5-HT2A-type in particular [40], salvinorin 
A acts as a selective κ -opioid receptor agonist [41, 42], as 
corroborated by recent X-ray crystal structure studies [43]. 
The analgesic and antiinflammatory activities of salvinorin 
A are of particular interest [44, 45]. There is also intensive 
research to explore the therapeutic potential of structurally 
related opioid receptor agonists or antagonists [46, 47]. 
For example, the hydrolytically stable salvinorin B 2-O-
ethoxymethyl ether is several-fold more active as a κ-opioid 
receptor ligand than the natural product [48]; users’ experi-
ence reports indicate that this semi-synthetic ether, named 
“Symmetry”, is at least as potent as salvinorin A5. Interest-
ingly, replacement of the 2-O-acetyl group of salvinorin A 
with a benzoyl group provides salvinorin B 2-O-benzoate 
(herkinorin), which is, in turn, a selective µ-opioid receptor 
agonist with antinociceptive activity in vivo [49, 50].
Preliminary experiments indicated low rodent toxicity 
[51] but no other study has examined the acute or chronic 
physiological adverse effects of Salvia divinorum leaves or 
extracts.
The vegetatively propagated plant as well as dried leaf 
preparations, often enriched with extracts from other S. 
divinorum leaves, are widely available but pure salvinorin A 
is rarely encountered. Analyses of Salvia leaf samples ob-
tained from various vendors indicated large variations in 
salvinorin A content (0.13-5.0 mg/g) [52, 53]. The plant 
and/or salvinorin A are controlled in an increasing number 
of countries.
Lysergamide
The discovery and psychopharmacology of LSD (from 
the German “Lysergsäure-diäthylamid”) have been well 
documented [54, 55]. LSD is a semi-synthetic compound 
usually prepared from lysergic acid, which is obtained hy-
drolytically from ergot alkaloids produced for the phar-
maceutical industry by fermentation of Claviceps fungi. 
Lysergamide (LSA, ergine or LA-111; Figure 1) was first 
obtained as a semi-synthetic product by the degradation of 
ergotoxin by Smith and Timmis in 1932. In 1960, Hofmann 
and Tscherter isolated it as a genuine natural product from 
“ololiuqui”, the seeds Rivea corymbosa (syn. Turbina corym-
bosa), the sacred narcotic-hallucinogen of the Aztecs. Since 
then LSA has been found in several ornamental morning 
glory (Ipomoea) species [56, 57]. The total ergot alkaloid 
content of the seeds of these plants is less than 0.2% with 
LSA and its 8-epimer (iso-LSA) being the most abundant. 
Figure 1
Chemical structure and common name of psychoactive sub-
stances of natural origin (a name in italics indicates a most 
likely man-made compound).
4. For further details, see: www.emcdda.europa.eu/publications/drug-
profiles/salvia. 
5. Information available from www.erowid.org/chemicals/salvinorin_b_
ethoxymethyl_ether. 
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Table 1
Chronology of selected psychoactive natural products
Ingestion of 50 to 100 seeds is needed to produce observ-
able effects. Phytochemical screening of tropical climbing 
vines led to the discovery of LSA in the seeds of the Hawai-
ian baby woodrose (Argyreia nervosa) [58]. Interestingly, it 
is not the seeds but the leaves A. nervosa that are used in 
Ayurvedic medicine in India, where the plant is indigenous. 
The LSA-content of A. nervosa seeds shows high variability 
between batches and may reach 1% [59]. Five to ten seeds 
provide intoxication that lasts for 4-8 hours. Recent studies 
indicate that LSA and related alkaloids are not biosynthe-
sized by the plant but produced by an associated fungus, 
which can be eliminated by fungicide treatment [60, 61]. 
Lysergamide and other alkaloid toxins are often present 
in endophyte-infected grasses and may cause poisoning in 
grazing animals [62].
Ergot alkaloids are “dirty drugs”: they bind to several 
receptors thus eliciting a broad range of effects. However, 
neither the seeds, nor LSA induce classical hallucinations: 
rather, the (psycho)pharmacological effects are sedative-
narcotic with feeling of complete emptiness [63]. The ob-
served vegetative and psychotropic effects can be rational-
ized by the results of recent in vitro studies revealing that the 
receptor profile of LSA is different from that of LSD [64]. 
The unpleasant effects of intoxication include salivation, 
nausea, diarrhea, tremor as well as psychosis, unpredictable 
behavior and even suicidal ideation [65-68]. 
Lysergamide is not listed in the UN Conventions, though 
it may be controlled either as a psychotropic substance or a 
precursor in some countries. The trade and sale of Ipomoea 
and A. nervosa seeds are largely uncontrolled.
Ayahuasca and its constituents
Ayahuasca or ayawaska (“vine of the souls”), also known 
as hoasca, caapi or yagé, is an ancient hallucinogenic decoc-
tion traditionally used in northern South America in ethno-
medicine and, since the 1930s, as a sacrament by syncretic 
religious sects, such as the União do Vegetal or the Santo 
Daime in Brazil6. The key ingredients in the brew are the 
Active principle Original or common source(s) Isolation Structure1 Psychoactivity type2
Morphine Papaver somniferum 1805 1925 narcotic-sedative
Caffeine Coffea arabica, Camellia sinensis, Cola nitida, Paul-linia spp. 1820 1882 stimulant
Nicotine Nicotiana tabacum, Duboisia spp. 1828 1893 stimulant
Hyoscyamine Atropa, Brugmansia, Datura, Duboisia spp. 1833 1897 hallucinogen/narcotic
Harmala alkaloids Peganum harmala, Banisteriopsis caapi 1841-1885 1919
hallucinogen/sedative, 
monoamine oxidase 
inhibitor
Cocaine Erythroxylum coca, E. novogranatense 1860 1898-1923 stimulant
Kavalactones3 Piper methysticum 1860-1959 1927-1959 anxiolytic/sedative
Ephedrine Ephedra equisetina (ma huang) and other Ephedra spp. 1887 1889 stimulant
Bufotenine Bufo toads; Anadenanthera trees 1893 1934 hallucinogen
Mescaline Lophophora williamsii, Echinopsis (Trichocereus) spp. 1896 1919 hallucinogen
Ibogaine Tabernanthe iboga 1901 1957 stimulant/hallucinogen
Mitragynine Mitragyna speciosa 1921 1963-1964 stimulant/sedative
Psilocybin Psilocybe (Stropharia), Conocybe, Inocybe, Paneolus spp. 1958 1958 hallucinogen
5-MeO-DMT Dictyoloma, Piptadenia and Mimosa spp.; Bufo al-varius 1959 1959 hallucinogen
Lysergamide Rivea (Turbina) corymbosa, Argyreia nervosa, Ipo-moea tricolor 1960 1960 hallucinogen
Muscimol Amanita muscaria, A. pantherina 1964 1964 hallucinogen
∆9-THC Cannabis sativa 1964 1964 sedative/hallucinogen
Ayahuasca4 Banisteriopsis caapi plus Psychotria viridis    -- 1972 hallucinogen
Cathinone Catha edulis 1975 1975 stimulant
Salvinorin A Salvia divinorum 1982 1982, 1984 hallucinogen
 1In some cases the structure was established independently by more than one research group.
 2The type of activity may depend on dose.
 3The first kavalactone to be identified was methysticin. Other 17 kavalactones, such as kavain and yangonin, were characterised subsequently.
 4The main constituents of ayahuasca, i.e., harmala alkaloids and DMT, had been known from other plants before their identification in the brew.
6. Ayahuasca has been the subject of several scholarly edited books (see, 
e.g., [69, 70]). The renewed global interest in ayahuasca, as made and used 
in South America, and ayahuasca-like preparations based on other plants 
indigenous to other continents, as well as the plethora of studies published 
recently on its use and effects justify a brief historical description as well 
as an update on studies not only of the brew but also its key ingredients.
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pounded bark of the Amazonian woody liana Banisteriopsis 
caapi and the leaves of either the shrub Psychotria viridis or 
the vine Diplopterys cabrerana. The drink is usually made 
by mixing the two key components in boiling water. Ad-
mixtures, mostly solanaceous plants containing nicotine 
or tropane alkaloids, are occasionally added. Drinking the 
brew often induces vomiting, while the cardiovascular ef-
fects (bradycardia and reduced blood pressure) are only 
mild; mydriasis is typically observed. The psychotropic ef-
fects, accompanied by vivid visual imagery, usually last for 
4-6 hours [71-73]. The side effects and relative safety of 
ayahuasca use have been reviewed [74, 75]. The physiologi-
cal and psychological mechanisms of the promising anti-ad-
diction effects of the brew offered in religious setting have 
recently been discussed [76].
The chemicals responsible for the dreamlike, colorful 
hallucinogen effects elicited by the brew were identified by 
Rivier and Lindgren in 1972: of the two plants, B. caapi 
is the source of harmala alkaloids, while P. viridis provides 
N,N-dimethyltryptamine (DMT) (Figure 1) [77, 78]. The 
first harmala alkaloid from the seeds of Syrian rue, Peganum 
harmala, was isolated by Goebel in 1841, while structural 
determinations were carried out by Manske et al. in 1927. 
These alkaloids, such as harmine, or 7-methoxy-1-me-
thyl-9H-b-carboline (Figure 1), and its di- or tetrahydro 
derivatives, are not particularly psychoactive on their own 
but, mainly in the gastrointestinal tract, inhibit monoam-
ine oxidase (MAO) enzymes involved in the metabolism of 
monoamine neurotransmitters and certain xenobiotics [79, 
80]. Passion flowers (Passiflora spp.) also contain harmala 
alkaloids but only in trace amounts; the pharmacological 
effects of preparations made from the plant are probably 
due to its flavonoid constituents [81, 82].
The primary hallucinogen component of ayahuasca is 
DMT, a low-melting point solid. The alkaloid was isolated 
from the seeds of Piptadenia (syn. Anadenanthera) species 
by Fish et al. in 1955 although it had already been synthe-
sized by Manske two decades earlier. DMT, along with 
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), is 
also a psychoactive component of South American ceremo-
nial snuffs prepared from Anadenanthera, Mimosa or Virola 
plants having various local names (cohoba, ebene, paricá, 
yopo, etc.) (see, e.g., [83]). The psychoactivity and metabo-
lism of DMT in humans were first studied by Szára in in-
jection experiments in Hungary in the mid-1950s. Like all 
classical hallucinogens, DMT activates 5-HT2A receptors in 
vitro. However, due to rapid inactivation by MAO enzymes, 
DMT is devoid of activity when taken orally explaining why 
the ritually or “recreationally” used DMT-preparations are 
administered either nasally or by inhalation to give hallu-
cinations lasting for 15-20 minutes only. Ayahuasca is thus 
a unique, synergistic ethnobotanical drink in which the 
MAO-inhibitory action of harmala alkaloids enable the 
manifestation of the hallucinogen effects of the metaboli-
cally labile DMT.
There is no record on how or why these two particular 
plants were selected from the rich biodiversity of the Ama-
zonian forest for the brew. The present author speculates 
that the ancient shamans initially experimented with a 
complex concoction made from several, perhaps dozens of 
plants. Having discovered activity of such a mixture, they 
could then proceed by using the leave-one-out technique, 
that is testing one by one a series of mixtures lacking just 
a single ingredient. This would then quickly reveal which 
plants are indispensable for activity. Reconstituting a brew 
from the key components would then validate the proce-
dure. It should also be pointed out that the brew contains 
other bioactive substances the contribution of which to the 
overall psychobiological activity has not been studied. The 
term “endohuasca” refers to human endogenous alkaloids 
chemically identical or similar to those present in the brew 
[84]; the actual (psycho)pharmacological role, if any, of 
such trace tryptamine metabolites is unknown [85]. The 
popular term “pharmahuasca” refers to the concomitant 
use of a synthetic MAO inhibitor with a tryptamine-type 
natural or synthetic hallucinogen [86].
Adopting practices of religious ayahuasca use, a num-
ber of follower groups have been established outside the 
Americas in recent years. While harmala alkaloids are 
regulated in a few countries only, DMT is an internation-
ally scheduled psychotropic substance. In the USA, the 
sacramental use of “hoasca” falls under the “Religious 
Freedom Restoration Act” [87]. Nevertheless, the bloom-
ing “ayahuasca tourism” in Amazonia as well as the spread 
of ayahuasca and related preparations beyond traditional 
cultural boundaries have raised concerns and elicited de-
bates on their regulation [88].
Bufotenine
Bufotenine, that is 5-hydroxy-N,N-dimethyltryptamine 
(Figure 1), is an N-alkylated derivative of serotonin and 
also a structural isomer of the hallucinogenic psilocin, 
the 4-hydroxy counterpart. The chemical structure of bu-
fotenine7 was established by synthesis by Wieland et al. in 
1934. Bufotenine and its ether derivative, 5-MeO-DMT, 
are the main ingredients of the psychoactive secretion of 
the American desert toad, Bufo alvarius. In fact, 5-MeO-
DMT is one of the few psychoactive substances found in 
animals, and the hallucinogenic properties of this alkaloid is 
most likely behind the contemporary myth that “toad lick-
ing” elicits psychedelic effects [90]. The psychoactivity of 
bufotenine, however, is contested [85, 91]. Accompanying 
congeneric tryptamines, bufotenine also occurs in several 
hallucinogenic plants (see, e.g., [92]). Interestingly, 5-MeO-
DMT is oxidatively demethylated to bufotenine in the body 
[93]. The alkaloid binds to 5-HT2A receptors in vitro with an 
affinity similar to that of DOB: the respective Ki values are 
2.7 and 3.7 nM [7]. When taken orally, however, it lacks 
psychoactivity due to rapid inactivation by MAO enzymes 
[93-95]. Bufotenine is not listed in the UN Conventions 
yet it is controlled in a number of countries.
A related substance worth mentioning here is 5-methoxy-
tryptamine, mexamine or 5-MeO-T. This endogenous trace 
amine is a serotonin receptor agonist and an enigmatic mi-
nor metabolite of the multifunctional neurohormone mela-
tonin [96]. It has antioxidant and radioprotective effects in 
various biological systems but there is no information on its 
psychoactivity.
Ibogaine
The root of the tropical West African shrub Tabernanthe 
iboga is used in Gabon and Cameroon for its stimulatory 
and sedative-hallucinogenic properties. On one hand, the 
7. Bufotenine is an alkaloid and should not be confused with bufotoxins, 
or bufadienolides, which are cardiotonic steroids also present in toad 
skin and are the main bioactive ingredients of “Love Stone”, an alleged 
aphrodisiac sold in some countries [89].
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bitter roots of the plant, locally called iboga, are chewed 
to combat fatigue and to keep hunters awake. Based on 
such ethnopharmacological observations, a root extract 
(Lambaréne®) was available in France (1939-1966) as “neu-
romuscular stimulant”. On the other hand, consumption 
of massive doses of iboga is part of the initiation ritual of 
the local Bwiti cult during which the initiate fells in deep 
coma that may last for a day. Of the structurally related alka-
loids isolated from the plant the most important is ibogaine 
(12-methoxyibogamine) (Figure 1), which is most abundant 
in the root bark (0.2-0.6%). The isolation of the light- and 
air-sensitive crystalline ibogaine was reported first in 1901, its 
structure was determined by Taylor in 1957. As with the root, 
ibogaine is stimulant at low (< 200 mg), while hallucinogenic 
at high (500-1000 mg) oral doses. The anti-addictive poten-
tial of ibogaine has received attention recently. In preclinical 
animal studies, acute ibogaine treatment reduced self-ad-
ministration or symptoms of withdrawal of various addictive 
drugs, including ethanol, methamphetamine, nicotine and 
morphine. In humans, single or repeated oral doses of 4-25 
mg/kg have been shown to alleviate withdrawal symptoms 
and craving, confirming anecdotal reports and patent claims 
originating from the 1960s [97-99]. However, due to serious 
adverse side effects, such as tremor, ataxia, cardiac toxicity 
and even fatalities, NIDA-coordinated human clinical trials 
were halted in 1995 [100-102]. According to recent stud-
ies, the alkaloid, at therapeutic concentrations, disrupts the 
heart’s electrophysiology that could lead to life-threatening 
cardiac arrhythmias [103, 104]. In rodent models of ethanol-
addiction, certain synthetic analogues have improved toxico-
logical profile and appear to be as effective as the natural 
alkaloid [105]. Ibogaine and its demethylated metabolite, 
namely 12-noribogaine (12-hydroxyibogamine) (see, e.g., 
[106]), have complex pharmacology affecting several neu-
rotransmitter and transporter systems [99, 107, 108]. The 
glial cell line-derived neutrophic factor, which is necessary 
for the proper functioning of dopaminergic neurons, appears 
to be also involved in the sustained anti-addictive effects of 
the alkaloid [109]. In the mouse, ibogaine was more toxic 
than 12-noribogaine (the respective intragastric LD50 values 
are 263 and 630 mg/kg) [110]. In spite of the health risks, 
controversial “ibogaine anti-addiction therapies” continue 
in private clinics and non-clinical setting in some countries 
where the substance is not regulated. Ibogaine is seldom 
used recreationally.
Kratom
Kratom (Mitragyna speciosa)8, or “krathom” (Thailand) 
and “biak” or “ketum” (Malaysia), is a tropical tree indig-
enous to South East Asia, the Philippines and New Guin-
ea. Traditionally, the chopped fresh or dried leaves of the 
tree are chewed or made into tea. Kratom preparations 
have been used in local medicine, and also as stimulants 
or an opium substitute. Of the over 40 structurally related 
alkaloids isolated from various parts of the tree the most 
abundant (up to 2% in the leaves and leaf preparations) is 
mitragynine (9-methoxycorynantheidine) (Figure 1) [111-
113]. The alkaloid was isolated first by Field in 1921, its 
chemical structure was clarified by Joshi and Zacharias in 
1963-1964. A minor though pharmacologically important 
alkaloid, namely 7-hydroxymitragynine, was discovered in 
the leaves by Ponglux et al. in 1994. There are few human 
clinical studies with kratom or its alkaloid constituents [114-
116]. At a low dose, leaf preparations act as “cocaine-like” 
stimulants and are traditionally used to combat fatigue dur-
ing work. At high dosages (10-25 g of dried leaves), how-
ever, “morphine-like” sedative-narcotic effects manifest: the 
initially occurring sweating, dizziness, nausea and dyspho-
ria are superseded with calmness, euphoria and a dreamlike 
state lasting for several hours. Contracted pupils (miosis) 
are also noted. Regular kratom use may cause constipation, 
anorexia and hyperpigmentation of the cheek; dependence 
may develop [117]. Withdrawal symptoms are relatively 
mild and typically diminish within a week [118].
The narcotic and antinociceptive effects of kratom are 
attributed to mitragynine and 7-hydroxymitragynine act-
ing as µ-opioid receptor agonists [113]. In this respect, 
7-hydroxymitragynine is several times more active than 
morphine both in vitro and in vivo. Recent studies revealed 
the roles of κ -opioid and dopamine D1 receptors in the 
various effects of kratom [119]. The serotonergic and adr-
energic systems are also involved in the psychological and 
physiological effects of mitragynine. The pharmacological 
mechanisms responsible for stimulant activity are yet to be 
established.
According to animal studies, kratom is only slightly 
toxic [120]. In rats, for example, oral administration of a 
kratom leaf-extract (1.6% mitragynine content) at 1000 
mg/kg caused transient toxicity (slow movement and rapid 
breathing) but no mortality, while morphine had depressant 
activity with 25% mortality at 430 mg/kg; oral mitragynine 
doses as high as 806 mg/kg were not lethal. Intravenous 
injection of mitragynine at 9.2 mg/kg to rhesus monkeys 
produced only transient toxic symptoms. In mice, repeat-
ed 7-hydroxy mitragynine administrations elicit tolerance, 
cross-tolerance to morphine, and naloxone-precipitated 
withdrawal symptoms [121]. There have been few poison-
ing cases related to kratom consumption [122-124].
In Asia, local shops may sell fresh kratom leaves in bun-
dles, while in foreign countries crushed or powdered dried 
leaves are available. Herbal products fortified with kratom 
leaf extracts are also marketed worldwide. It is of note that 
fatal intoxications involving fake kratom preparations adul-
terated with O-desmethyltramadol, a bioactive metabolite 
of the synthetic opioid analgesic tramadol, have recently 
been reported [125]. Fentanyl-laced kratom-preparations 
have also been seized in the USA [126].
Although still uncommon – and mostly unregulated – 
outside Asia, kratom has become one of the most widely 
abused illicit substances in Malaysia and Thailand either as 
a drug by itself or a substitute for opium or alcohol [117, 
127, 128].
Kava
Kava, awa, yaqona or “intoxicating pepper” (Piper methys-
ticum) is a large-leaved shrub indigenous to the South 
Pacific Islands. It is also the name of the mildly narcotic 
beverage made by extracting the rootstocks of the plant 
by water at ambient temperature. On many of the Islands, 
kava drinking is an integral part of social life. The plant was 
probably first domesticated in Vanuatu and, by now, it has 
spread throughout the region. The many different cultivars 
(or chemotypes) grown on the Islands today have been se-
lected over generations; the clones are propagated vegeta-
tively. Kava products, either the dried and powdered roots 
8. For further details, see: www.emcdda.europa.eu/publications/drug-
profiles/kratom. 
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or root organic solvent extracts, are important agricultural 
commodities in that region with annual export values ex-
ceeding US$ 11 million [129]. Kava preparations have also 
been used in traditional medicine to cure fever, pain, head-
ache, respiratory problems, insomnia, diarrhea or constipa-
tion, skin diseases, convulsion, urogenital and menstrual 
problems. In the early twentieth century, kava products 
were sold in Europe for the treatment of various illnesses 
[130]. The effects of the drink include mild euphoria and 
sociability, as well as anesthesia and astringency in the 
tongue and the inner lining of the mouth. Small doses 
typically produce stimulation while larger ones cause 
muscle relaxation, incoordination, and somnolescence. 
Regular and heavy use of kava, either the drink or the 
extracts, is not without risks: transient dermopathy (dry 
scaling skin), liver and kidney problems, gastrointestinal 
distress, as well as impaired vision have been observed 
[131, 132].
Since the initial studies on the separation of the indi-
vidual kava-constituents by Cuzent around 1860 and by 
Lewin in the mid-1880s, the phytochemistry of P. methys-
ticum, has been fully explored [133, 134]. The psycho-
active principles of the roots are the so-called kavalac-
tones (kavapyrones), exemplified by kavain (also spelled 
kawain) and yangonin (Figure 1). The total kavalactone 
content may vary from 3 to 20% of the dried root. The 
composition of the aqueous beverage and the organic ex-
tracts mainly depends on the type of the cultivar though 
environmental factors and the extraction method em-
ployed also affect the kavalactone content [135, 136].
The mode of action of kava in the central and periph-
eral nervous system is complex and not fully understood. 
Each kavalactone has a distinct pharmacological profile 
involving GABA and benzodiazepine receptor sites, 
voltage-gated cation channels, monoamine reuptake and 
metabolism, the arachidonate cascade, and the endo-
cannabinoid system [131, 137]. Accordingly, there can 
be substantial variations in the effects between various 
chemotypes; drinkers are said to prefer cultivars with 
high kavain content [136]. It must also be noted that 
constituents other than the kavalactones may play a role 
in the various pharmacological or pathophysiological 
effects of the aqueous extract though this issue has re-
ceived scant attention (see, e.g., [138, 139]).
In recent decades, kava root extracts, formulated as 
capsules or tinctures, became available worldwide as di-
etary supplements and clinically proven over-the-counter 
medicines for anxiety, depression and insomnia [131, 
140]. Since 2002, however, several European countries 
restricted the sale of such extracts due to reports about 
hepatotoxicity of still unresolved etiology [141-143]. 
Nonetheless, dried and finely ground roots, having a 
light greyish-brown color resembling sawdust, are of-
fered in herbal shops and on the Internet. Because of the 
economic importance on one hand and of the uncertain-
ties of the health risk associated with kava products on 
the other, the developments of regional and FAO-WHO 
Codex Alimentarius standards for kava have been rec-
ommended9. A few countries have, in recent years, regu-
lated kava as a psychotropic drug.
Betel
After caffeine-containing beverages and tobacco, be-
tel is the third most widely used stimulant: it is chewed 
regularly by at least 400 million people throughout east 
Africa, Asia and the Pacific Islands as well as migrant 
communities therefrom [144-147]10. Betel or, more ac-
curately, a betel quid is made of three essential ingre-
dients: slices of nuts of the areca palm (Areca catechu), 
spread with slaked lime and wrapped in the heart-shaped 
leaf of the betel palm (Piper betle). Tobacco may be a 
common ingredient and spices, such as aniseed, carda-
mom, cloves, coconut, ginger, nutmeg or sugar, are fre-
quent flavoring additives. In India, the sale of tobacco-
containing betel products known as “gutka” was restrict-
ed in 2011. Freshly prepared quids are usually sold by 
street vendors or, in Taiwan, by “betel nut beauties” along 
busy roads. The quids are placed between the cheek and 
the tongue, pressed against the teeth to remove the juice, 
which is then swallowed. Due to the coloring ingredients 
of the nuts, the reddish spittle stains the chewer’s gums 
and lips (as well as the roadside…). Industrially manufac-
tured, tobacco-free areca products called “pan masala” 
are sold in convenient sachets. Fresh or dried nuts, called 
“supari” in India, cut into small pieces may also be mas-
ticated alone. Areca and betel preparations have been 
used in traditional, for example Ayurvedic, medicine for 
centuries. Areca nut is a commodity in Asia with about 
650 000 tonnes produced annually [149]. Bulk quantities 
of synthetic arecoline salts have also appeared recently in 
on the Internet for sale.
The alkaloid constituents of areca nut were structur-
ally characterized by Jahns in 1888-1891. The principal 
alkaloid is arecoline, namely the methyl ester of 1-methyl-
1,2,5,6-tetrahydropyridine-3-carboxylic acid (Figure 1), a 
nicotinic acid derivative. The arecoline content of the nuts 
may reach 1%. Arecoline, a colorless liquid, can readily be 
synthesized and its salts are deworming (purgative) agents 
used in veterinary medicine. There are three other related 
alkaloids present in the nut: arecaidine, which is the free 
carboxylic acid derivative of arecoline formed also during 
mastication and ingestion; guvacine, which is the N-des-
methyl derivative of arecaidine; and guvacoline, which is 
the N-desmethyl derivative of arecoline.
The leaves of the betel palm contain phenylpropanoids, 
such as chavibetol (Figure 1), eugenol and safrole, as well 
as terpenes but the contribution of these aroma constitu-
ents to the psychoactivity of the quid is not known.
In spite of widespread use, the physiological and psy-
chological profile of betel quid intoxication is just be-
ginning to be delineated [150]. More is known about 
the pharmacology and toxicology of its alkaloidal con-
stituents [151]. The active ingredients, absorbed into the 
blood via the mucous membranes of the mouth and the 
intestine, affect both the central and peripheral nervous 
systems. Betel, due to its predominant alkaloid, areco-
line, which is a known muscarinic acetylcholine receptor 
agonist, elicits mostly cholinergic (parasympathomimet-
ic) symptoms and elevated adrenaline plasma concentra-
tions. The minor alkaloids are GABA uptake inhibitors 
and presumably modulate the psychoactivity of the quid.
9. See: http://acp-mts-programme.org/en/contents/pacific-high-level-
meeting-on-kava-12-15-march-2012 and ftp://ftp.fao.org/codex/
meetings/CCNASWP/CCNASWP12/na12_08e.pdf. 
10. For the historical and cultural aspects of as well as artistic utensils 
associated with betel chewing, see the lavishly illustrated book by 
Rooney [148].
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The typical psychological effects are mild and include 
relaxation, light euphoria and improved concentration. 
Somatic symptoms include miosis, intense salivation, fa-
cial flushing, sweating, palpitation, bronchoconstriction 
(risk of asthma!), and increased gastrointestinal motility, 
though chronic users develop tolerance to many of these 
effects. Novice users or regular chewers ingesting large 
amounts may experience tremor, dizziness, diarrhoea, 
vomiting and acute psychosis.
Excessive use of areca nut and betel quid has been 
associated with a number of health-related problems: 
discoloration of teeth and gums, sometimes turning red-
dish-brown, mouth ulcers and gum disease, oral submu-
cous fibrosis and oral cancers, including squamous cell 
carcinoma, peptic ulceration, increased risk of cardiovas-
cular disease. The major concern of betel chewing is the 
risk for the development of oral cancer associated with its 
alkaloid ingredients and, in particular, their nitroso and 
N-oxide derivatives [152,153]. The risk of malignant oral 
disorders increases when tobacco is included in the quid 
[154]. Recently, however, Rai et al. [155] have proposed 
that some non-alkaloidal phytochemicals (polyphenols 
and terpenoids) present in betel palm leaves may, by 
various mechanisms, counteract the carcinogenic effects 
of areca and tobacco alkaloids. Due to its cholinergic 
effects, arecoline may clinically improve the cognitive 
performance of Alzheimer’s patients [156]. Dependence 
and withdrawal symptoms have been noted [157]. Few 
countries regulate the palm or its alkaloids.
LESSER-KNOWN PSYCHOACTIVE NATURAL 
PRODUCTS
Glaucine
The alkaloid glaucine, also known as boldine dime-
thyl ether or 1,2,9,10-tetramethoxyaporphine (Figure 1), 
is found in the yellow horned poppy (Glaucium flavum, 
formerly G. luteum), indigenous to the Mediterranean 
region, as well as in other plants, such as Croton lechleri 
(source of the latex “sangre de grado”) or the Chinese 
medicinal plant Corydalis yanhusuo. The alkaloid was 
isolated by Fischer in 1901, its structure determined 
by Gadamer in 1911. Glaucine can also be synthesized 
either from the readily available boldine or, in racemic 
form, from papaverine. The therapeutic value of glau-
cine is similar to that of codeine or dextromethorphan 
[158, 159] but with lower abuse potential [160]. The 
plant has been used in folk medicine while glaucine it-
self is registered in some East European countries as an 
over-the-counter, non-opioid antitussive and bronchodi-
latory medicine. The alkaloid was shown to be an effec-
tive blocker of calcium ion channels of bronchial smooth 
muscles, as a week antagonist of dopamine receptors, 
as an antagonist of peripheral serotonin receptors, as a 
non-selective α-adrenoreceptor antagonist, as a selective 
inhibitor of phosphodiesterase type 4 isoenzyme, as an 
antioxidant and a resensitizer of multidrug resistance of 
cancer cells (see, for example, [161]). Glaucine has been 
reported to cause weakness, sleepiness, nausea, mydria-
sis and visual or dissociative-hallucinations both with 
therapeutic and recreational use but the underlying phar-
macology responsible for these central effects remains to 
be determined [162, 163]. Glaucine-containing tablets 
and herbal mixtures have appeared recently as “herbal 
highs” in the several European countries [162, 164, 165].
Pituri
Pituri, pitchery or chewing tobacco (Duboisia hopwoodii), 
is a solanaceous shrub growing in the arid region of Aus-
tralia. Its dried and powdered leaves, often mixed with ash 
obtained from the burning of some other plant, are made 
into a quid, which is then chewed by Aboriginal groups to 
alleviate fatigue, hunger and pain; plant preparations are 
also used to kill game and fish [166]. The identity of one 
of the alkaloids in the leaves was unequivocally confirmed 
in 1911 by Rothera as the cholinergic nicotine (Figure 1). 
The roots of D. hopwoodii are, however, particularly rich in 
anticholinergic tropane alkaloids, e.g., hyoscyamine, also 
called duboisine or daturine (Figure 1), and its 6,7-epox-
ide, scopolamine. Related alkaloids have also been isolat-
ed from the leaves and roots of other Australian Duboisia 
(corkwood) species since the 1870s [167], and are of eth-
nopharmacological interest. Such deliriant tropanes are the 
principal bioactive alkaloids of many solanaceous plants, 
including the legendary Atropa (belladonna), Brugmansia 
(angel’s trumpet), Datura (jimsonweed, thornapple), Man-
dragora (mandrake) and Solandra (chalice vines) species. 
Some Solandra species called “cup of gold” are woody, tree-
like climbers indigenous to Mexico and tropical America 
and were once used by the Aztecs as sacred hallucinogen 
(“tecomaxochitl”); the plants are still revered in Mexico by 
Huichol Indians who call them “kiéri” [168]. Hyoscyamine 
is used in medicine in some countries, for example in an-
tiulcer therapy, while scopolamine and its derivatives are 
employed in veterinary and human medicine; for example, 
transdermal scopolamine formulations, to prevent nausea 
and motion sickness [169]. The not uncommon abuse of 
Datura species to induce hallucinations is often associ-
ated with severe complications, although these are rarely 
fatal (see, e.g., [170, 171]). Pure scopolamine or Datura 
and Brugmansia preparations (“burundanga”; popularized 
as Devil’s breath) cause transient amnesia and their use to 
incapacitate crime victims, especially in Colombia, is well 
documented [172, 173].
Wild lettuce
Wild lettuce, bitter lettuce or lettuce opium (Lactuca vi-
rosa), wildly growing in Eurasia and Northern Africa, is a 
tall (up to 150 cm high), poisonous and skin irritating rela-
tive of the garden lettuce (L. sativa). The analgesic, sedat-
ing, hypnotic and cough-suppressing properties of its seed 
extracts and of the milky latex (lactucarium), released from 
its stem and leaves upon wounding, have been known for 
millennia [2, 174]11. Lactucarium is obtained from L. virosa 
or L. sativa and used like opium in traditional medicine 
and various preparations form these species were listed in 
pharmacopoeias of several countries up to the early twenti-
eth century. The smoked dried leaves of the plant can also 
serve as marijuana substitute. In spite of the long history of 
its use, not much is known about the pharmacology of L. 
virosa and of its chemical constituents. The latex contains 
bitter sesquiterpene lactones thought to be responsible for 
the characteristic pharmacological properties of the plant 
[176]. One of the most studied sesquiterpene is lactucin 
(Figure 1), which is present either in free or esterified form 
11. The sesquiterpene lactones present in the latex have ecological 
importance: these bitter and chemically reactive substances are part of 
the defense mechanism against predators (for a recent review covering 
human health related adverse effects, see [175]).
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also in other lettuce species as well as in chicory. Crystalline 
lactucin was isolated in pure form by Schenk and Graf in 
1936 and its bicyclic lactone structure, related to that of the 
bitter principle of absinthe, was established independently 
in the laboratories of Barton and of Šorm in 1958. Apart 
from the (user-)reported narcotic-euphoric effects resulting 
form recreational use, there is scant contemporary informa-
tion on the (psycho)-pharmacological properties of either 
the latex or its pure ingredients [174]. The sedative and an-
algesic activities of lactucin were confirmed in mice though 
opioid receptors were unaffected in vitro [177, 178]. The 
symptoms observed in human wild lettuce-poisoning cases 
differ from those of traditional opiates [179, 180]. The pre-
cise molecular targets of the latex and its constituents are 
yet to be established. Wild lettuce preparations, including 
fortified extracts, are freely offered on many Internet sites 
and by herbal (smart) shops.
Kanna
Kanna, channa or sceletium (Mesembryanthemum - for-
merly Sceletium - tortuosum) is a creeping perennial plant 
with succulent leaves. It is indigenous to southern Africa 
where it has traditionally been used (mainly chewed as 
quid) by the Khoe-San people to elevate mood, relieve 
hunger and thirst. The psychoactivity of this relatively lit-
tle studied plant and its “fermentation” product (“kougoed” 
in Afrikaans) is attributed to a structurally related group of 
alkaloids of which the most abundant is mesembrine (Fig-
ure 1). Mesembrine was isolated by Zwicky in 1914 and its 
structure identified in 1960 (see [181, 182]). Laboratory 
experiments with various plant preparations have revealed 
anti-stress, antidepressant, narcotic, anxiolytic and anti-ad-
dictive but not hallucinogenic effects [182, 183]. Screening 
in vitro a range of potential pharmacological targets revealed 
that mesembrine was an effective inhibitor of 5-HT reup-
take, while its unsaturated derivative (i.e., mesembrenone) 
inhibited both 5-HT reuptake and phosphodiesterase type 
4 isoenzyme [184, 185]. These results, at least partly, sup-
port the observed psychoactive properties of the plant.
Many Internet sites and herbal shops offer powdery 
kanna preparations, including fortified extracts, that vary in 
their mesembrine-type alkaloid-content and, consequently, 
in their psychoactivity [186]. In 2013, a standardized ex-
tract (Zembrin®) became available as a mood-enhancer and 
anxiolytic botanical supplement [185].
OBSCURE OR FALSE “NATURAL” 
PSYCHOACTIVE SUBSTANCES
There has been a resurgence of interest in natural prod-
ucts in general, and suppliers of dietary supplement and 
unregulated psychoactive substances try to profit from it. 
In recent years, however, chemical scrutiny have revealed 
that some herbal mixtures advertised as “natural” or “herbal 
high” contain undisclosed synthetic additives as bioac-
tive constituents. Fake kratom products adulterated with 
synthetic opioids have already been mentioned. A most 
dramatic development was the appearance on the drug 
market, in around 2004, of smokable herbal mixtures un-
der the brand name “Spice”, mimicking the effect of mari-
juana [187]. Since then, the number of herbal preparations 
laced with structurally diverse synthetic cannabinoid recep-
tor agonists, originally invented by academic or industrial 
research laboratories, has been growing incessantly [188-
190]. There have been, however, other cases for which the 
origin of psychoactive ingredients in the natural products 
was or still is enigmatic. A few selected but representative 
examples are mentioned below.
Clement et al. [191] reported the detection of psychoac-
tive phenethylamines, including mescaline as well as am-
phetamine and p-methoxyamphetamine, in Acacia species 
growing in southwest Texas and northern Mexico. No other 
analyses have substantiated these intriguing findings. Since 
drugs have been found to be ubiquitous in our environment, 
including air (see, e.g., [192]), it is suspected that the isolated 
compounds, the amphetamines in particular, were artifacts 
due atmospheric transport from the site of their production 
or use. A similar case concerns the sub-Saharan Nauclea lati-
folia (or N. esculentus), commonly known as pin cushion tree, 
African peach or Guinea peach, which has been used in local 
ethnomedicine for the treatment various ailments. Recently, 
the synthetic opioid analgesic tramadol has been isolated 
from the root bark of the plant [193]. Although the struc-
ture of the compound was unequivocally proven by multiple 
analytical methods, the true origin of this substance with a 
structure unprecedented in nature remains to be established. 
In the author’s opinion these two cases are most likely further 
examples of the so-called “semi-natural products”, defined 
recently as man-made substances that are (re)isolated from 
natural sources [194].
Another widely occurring natural phenethylamine is 
also worth mentioning here. Hordenine or N,N-dimethyl-
tyramine (p-hydroxy-N,N-dimethylphenethylamine; also 
known as anhaline) is a minor alkaloid not only of peyotl 
(Lophophora williamsii) and other cacti, but Acacia, Sceletium 
and Phalaris plants [195]. Since germinating barley (Horde-
um spp.) produces hordenine, the alkaloid is present in beer 
[196] and is readily identifiable in the urine of beer drinkers. 
Thus, its presence in urine should not be considered an indi-
cator of synthetic drug use, as proposed [197], but rather as 
an indicator of beer consumption [198]. The human psycho-
activity of hordenine is not known. It is of note, however, that 
this phenolic alkaloid could cause false positives in morphine 
immunoassays of beer drinkers’ urine [199].
The final case concerns a stimulant substance, namely 
1,3-dimethylamylamine or DMAA in short (systematic 
name is 4-methylhexan-2-amine; four stereoisomers exist) 
(Figure 1). It is often advertised as “geranamine” alluding to 
an obscure report on its detection in geranium essential oil 
(see: [200]). Recent studies, unable to identify this volatile 
amine in commercial geranium oil samples and food sup-
plements, refuted the claims that “geranamine” is natural 
product [201-203]. In fact, DMAA is one of the branched 
aliphatic amines synthesized by pharmaceutical compa-
nies in search for novel amphetamine analogues [204]. It 
was marketed as a nasal decongestant (Forthran®) until the 
1970s. The mild stimulant effect of DMAA is comparable 
to caffeine [205], but its use is not without health risk [206]. 
Though a prohibited doping agent, DMAA is a frequent 
ingredient of dietary supplements sold for athletes. Immu-
noassays developed for amphetamine-type drugs may show 
cross-reactivity with DMAA [207].
CONCLUSIONS
Tourism, migration, international trade as well as the 
boundless flow of information via the Internet all contrib-
ute to the global spread of many once exotic psychoactive 
drugs [208, 209]. Between January 2005 and December 
2012, some 230 new psychoactive substances have been 
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